Cerebras Systems, Inc. (CBRS) is a Sunnyvale, California-based AI chipmaker known for its "wafer-scale" processors — chips roughly the size of a dinner plate — that it sells as an alternative to traditional GPUs for AI inference. The company went public in May 2026, and Wall Street coverage is still relatively young but overwhelmingly bullish.
This analysis reviews nine individually attributable targets: UBS ($330), Citigroup ($320), Mizuho ($300), Rosenblatt ($300), Needham ($300), Barclays ($280), Wedbush ($280), Morgan Stanley ($279), and Freedom Capital Markets ($209). The arithmetic mean is approximately $289, which rounds to the $290 central target used here. The low-to-high range spans $209 to $330.
That spread is unusually wide for a semiconductor name, and it matters. Bulls such as Needham's Quinn Bolton and Rosenblatt's Kevin Cassidy argue the wafer-scale architecture gives Cerebras a memory and bandwidth advantage in fast inference, and they point to its large OpenAI agreement and an Amazon Web Services (Amazon) partnership. The cautious view, represented by Freedom Capital's Paul Meeks, applies a far lower multiple to account for execution and customer-concentration risk. Most firms rate the stock a Buy or Outperform, but the single most recent action was defensive: several analysts trimmed targets in August, and the latest call trimmed further to $209.
The stock closed near $166.43, meaning the $290 target implies about 74% upside. By any standard, that is a very large required move, not a modest step.
The gap reflects both growth and risk. Cerebras grew revenue from about $78.7 million in 2023 to roughly $510 million in 2025, and estimates point to about $887 million in 2026 and close to $2.95 billion in 2027. That trajectory, if delivered, would go a long way toward justifying a higher share price. But the stock is priced at roughly 217 times forward earnings, so the path to $290 depends less on ordinary progress than on sustained, above-consensus execution and on investors continuing to award a premium valuation.
The 52-week range runs from about $160.81 to $386.34, and shares have slipped below the $185 IPO price. Analysts have pointed to a post-IPO floor near $169; a sustained break below that area would signal deeper downside, while the $185–$200 zone represents the first meaningful resistance overhead. The $290 target sits far above both, implying the stock would need to reclaim its post-IPO highs before approaching it.
Analyst price targets generally reflect a roughly 12-month horizon, though individual firms vary in methodology and timing, and the wide target range signals low conviction about the exact level. Investors should watch quarterly earnings and guidance, any change in the OpenAI relationship or its mix of Nvidia versus Cerebras hardware, AWS deployment progress, insider selling following the lockup expiration, and any revisions to consensus revenue estimates. These factors, more than a single number, will determine whether the stock can close a 74% gap.
For traders monitoring a high-volatility name like Cerebras, AI Daily Buy/Sell Signals from Tickeron can help put price action into context. The tool uses artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single snapshot, traders can use it to discover new opportunities, monitor existing positions, and identify changing trends more efficiently — a useful complement to fundamental research when a stock is moving on sentiment as much as on earnings.
The $290 central target is an analyst-derived average, not a forecast or guarantee, and it sits roughly 74% above the current price. The bull case rests on triple-digit revenue growth, a differentiated wafer-scale architecture, and marquee partnerships with OpenAI and AWS. The bear case centers on customer concentration, intensifying competition from Nvidia, a demanding valuation, and a wave of insider selling. With targets ranging from $209 to $330, Wall Street itself is divided on the scale of the opportunity. Whether Cerebras can reach $290 ultimately depends on execution against an aggressive growth path and on investors' willingness to keep paying a premium multiple — questions that will be answered by earnings and customer developments, not by any single price level.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.